CHPF antibody (AA 51-150) (Cy5.5)
Quick Overview for CHPF antibody (AA 51-150) (Cy5.5) (ABIN5000020)
Target
See all CHPF AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 51-150
-
Specificity
- May have slight cross reactivity with CHPF2 due to sequence similarity of the following amino acids "RTRYI" within the immunogen
-
Cross-Reactivity
- Human
-
Predicted Reactivity
- Mouse,Rat,Dog,Cow,Sheep,Pig
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human CHPF
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- CHPF (Chondroitin Polymerizing Factor (CHPF))
-
Alternative Name
- CHPF
-
Background
-
Synonyms: Chondroitin sulfate synthase 2, Chondroitin-polymerizing factor, Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II, N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase II, N-acetylgalactosaminyltransferase 2
Background: Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Isoform 2 may facilitate PARK2 transport into the mitochondria. In collaboration with PARK2, isoform 2 may enhance cell viability and protect cells from oxidative stress.
-
Gene ID
- 79586
-
UniProt
- Q8IZ52
-
Pathways
- Glycosaminoglycan Metabolic Process, SARS-CoV-2 Protein Interactome
Target
-